@article{Viscardi2020,
abstract = {Malignant pleural mesothelioma (MPM) is an aggressive tumor strictly connected to asbestos exposure. Prognosis is dismal as diagnosis commonly occurs in advanced stage. Radiological screenings have not proven to be effective and also pathological diagnosis may be challenging. In the era of precision oncology, validation of robust non-invasive biomarkers for screening of asbestos-exposed individuals, assessment of prognosis and prediction of response to treatments remains an important unmet clinical need. This review provides an overview on current understanding and possible applications of liquid biopsy in MPM, mostly focused on the utility as diagnostic and prognostic test.},
author = {Viscardi, Giuseppe and Di Natale, Davide and Fasano, Morena and Brambilla, Marta and Lobefaro, Riccardo and De Toma, Alessandro and Galli, Giulia},
doi = {10.37349/etat.2020.00028},
journal = {Exploration of Targeted Anti-tumor Therapy},
keywords = {biomarkers,ctc,ctdna,liquid biopsy,malignant pleural mesothelioma,mesothelin,mesothelioma,mirnas},
pages = {434--451},
title = {{Circulating biomarkers in malignant pleural mesothelioma}},
volume = {1},
year = {2020}
}